

STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

STENOCARE A/S publishes Annual Report 2020

The Board of Directors and the Chief Executive Officer of STENOCARE A/S (“STENOCARE”) hereby publishes the annual report of the fiscal year 2020. The annual report including the auditor’s report is available as an attached file and on the websites of STENOCARE (<https://stenocare.com/investor-relations/>) and Nasdaq First North (<http://www.nasdaqomxnordic.com/shares/microsite?Instrument=CSE196164>).

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

“Despite the continued challenges for society and business caused by Covid19, STENOCARE made great progress with our ambitious growth plan. We raised DKK 51 mill capital for the strategic investments, became free of debt, entered a third country and started selling products to the market. This is a strong platform for the year to come”

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on March 4, 2021.

STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency’s permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

www.stenocare.dk

www.stenocare.se

www.stenocare.com